FPWR-supported scientists have recently published four important studies that provide new insight into MAGEL2, the gene affected in Schaaf-Yang syndrome (SYS) and Prader-Willi syndrome (PWS).
These studies represent an important step forward. To develop effective therapies, researchers first need to understand exactly what happens inside cells when MAGEL2 is not working properly. These new findings help answer some of those questions.
Together, the studies explore MAGEL2 in multiple tissues and from multiple angles: how it affects developing brain and heart cells, how it influences hormone-production in the pituitary gland, and how it works alongside another important protein called USP7.
The first study examined how MAGEL2 mutations affect the development of neurons, the cells that make up the brain and nervous system.
Researchers used a powerful approach called "multi-omics," which allows them to look at several cellular processes at the same time. Rather than studying only genes or only proteins, they examined multiple layers of cellular activity to build a more complete picture of what is happening inside developing brain cells.
The researchers found that MAGEL2 mutations disrupt several important processes involved in brain development. These changes affected how proteins are produced and regulated within neurons, ultimately altering how brain cells grow and mature.
One of the most important findings was that many of these changes were shared between Schaaf-Yang syndrome and Prader-Willi syndrome, suggesting that both conditions may involve common biological pathways, despite differences in the way MAGEL2 itself is altered.
By identifying these shared pathways, scientists can begin looking for treatment strategies that address the underlying causes of both disorders.
The second study focused on the pituitary gland, a small but powerful structure located at the base of the brain.
Often called the body's "master gland," the pituitary produces hormones that help regulate growth, metabolism, stress responses, and many other important functions.
Using a mouse model with an inactive MAGEL2 gene, researchers discovered that the loss of MAGEL2 disrupts protein production within pituitary cells. These changes affected many proteins involved in hormone production and cellular function.
This finding is particularly interesting because growth and hormone-related challenges are common in both SYS and PWS. Understanding how MAGEL2 affects pituitary function may help researchers better understand some of these symptoms and identify new areas for therapeutic development.
Another research group examined the heart and blood circulation in the same mouse lacking MAGEL2. They discovered significantly thicker muscle surrounding the left ventricle and consistent decreases in the ventricle's volume, and thus the amount of blood pumped per heartbeat. Further, researchers found increased activity of potassium channel protein TASK-1, potentially linking this cardiac change to MAGEL2's protein regulation functions.
Though these specific cardiac abnormalities are not common in humans with PWS or SYS, they may reflect subtle differences that could contribute to well-known exercise tolerance in these syndromes.
This work reminds us that MAGEL2 influences biology throughout the body, not just in the brain, and also the importance of comprehensive cardiovascular evaluation in PWS/SYS clinical management.
The final study zoomed in even further, examining MAGEL2 at the atomic level.
Researchers investigated how MAGEL2 interacts with another protein called USP7. These two proteins work together as part of a larger cellular system that helps regulate other proteins inside cells.
Proteins are constantly being built, modified, recycled, and removed. The MAGEL2-USP7 complex helps manage some of these processes, ensuring that proteins are available when needed and removed when they are no longer useful.
Using advanced structural biology techniques, the researchers mapped exactly how MAGEL2 and USP7 fit together. They also showed how disease-causing mutations can interfere with this interaction.
This detailed understanding is valuable because it identifies specific molecular mechanisms that may be disrupted in SYS and related neurodevelopmental disorders. It may also help researchers design future therapies that target these pathways.
Although these studies answer different questions, they all point toward the same goal: understanding what happens when MAGEL2 is not functioning normally.
Taken together, the findings reveal more about the important roles MAGEL2 plays in:
The research also highlights biological pathways shared between Schaaf-Yang syndrome and Prader-Willi syndrome, providing valuable clues for scientists working to develop future treatments.
Every new discovery helps build a clearer picture of how MAGEL2 functions in multiple parts of the body. That knowledge creates a stronger foundation for identifying therapeutic targets, testing new treatment approaches, and ultimately improving outcomes for individuals with SYS and related conditions.
While there is still much to learn, these four studies represent meaningful progress toward understanding the biology of Schaaf-Yang and Prader-Willi syndromes and finding effective therapies in the future.
Mechanisms of USP7/MAGEL2 Complex Assembly and Its Mutational Disruption in Neurodevelopmental Diseases https://doi.org/10.64898/2026.04.24.720667 *preprint, not yet certified by peer review